DADLE vs Somatostatin
Head-to-head comparison of DADLE ([D-Ala2, D-Leu5]-enkephalin) and Somatostatin (Somatostatin-14) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | DADLE | Somatostatin |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | [D-Ala2, D-Leu5]-enkephalin | Somatostatin-14 |
| Molecular Weight | 569.67 Da | 1637.85 |
| Half-Life | 5-20 minutes in plasma | 1-3 min |
| Amino Acids | 5 | 14 |
| Typical Dose | 0.01-2 ug per animal | N/A|N/A |
| Route | Intrathecal / intracerebroventricular | IV/SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 450 | 84 |
| Research Status | Pre-clinical | Approved |
DADLE Benefits
- ✓delta-opioid agonism
- ✓enhanced peptide stability
- ✓spinal analgesia models
- ✓research on tolerance mechanisms
Somatostatin Benefits
- ✓nociceptive inhibition
- ✓anti-inflammatory signaling
- ✓visceral pain modulation
DADLE Dosing
Intrathecal 0.01-2 ug per animal|Intracerebroventricular 0.01-1 ug per animal|In vitro 0.1-50 nM
Somatostatin Dosing
N/A|N/A
DADLE Side Effects
- ⚠sedation
- ⚠motor suppression at higher doses
- ⚠opioid tolerance with repeated exposure
Somatostatin Side Effects
- ⚠hyperglycemia
- ⚠bradycardia
- ⚠GI upset
Research Overview
DADLE
DADLE has been studied for analgesic, neuroprotective, and receptor-selective opioid effects in animal and tissue models. It remains important as a mechanistic probe because it is more stable than endogenous enkephalins but still peptide-like in its delivery constraints.
Somatostatin
Somatostatin reduces release of multiple excitatory mediators and can suppress pain signaling in preclinical and limited translational work. Its analgesic use is not standard, but the peptide is real and mechanistically relevant to pain control.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.